UPB
HEALTHCAREUpstream Bio Inc
$9.19+0.07 (+0.77%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving UPB Today?
No stock-specific AI insight has been generated for UPB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.25$33.68
$9.19
Fundamentals
Market Cap$500M
P/E Ratio—
EPS$-2.66
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume409K
Avg Volume (10D)—
Shares Outstanding54.4M
UPB News
23 articles- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceYahoo Finance·Apr 17, 2026
- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightGlobeNewswire Inc.·Apr 7, 2026
- From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation BlockerBenzinga·Apr 7, 2026
- Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst callsYahoo Finance·Mar 27, 2026
- Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More247 Wall St·Mar 27, 2026
- Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 26, 2026
- Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsightYahoo Finance·Mar 5, 2026
- Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingYahoo Finance·Mar 1, 2026
- Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026Yahoo Finance·Feb 26, 2026
- Upstream Bio to Participate in Upcoming March Investor ConferencesYahoo Finance·Feb 25, 2026
- Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%Marketbeat·Feb 16, 2026
- Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In GrowthYahoo Finance·Feb 15, 2026
- Upstream Bio’s stock drops 47% on verekitug Phase II asthma dataClinicaltrialsarena·Feb 12, 2026
- Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong DoseYahoo Finance·Feb 11, 2026
- Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe AsthmaYahoo Finance·Feb 11, 2026
- Evommune rockets on eczema data; AstraZeneca advances GLP-1 pillBiopharmadive·Feb 11, 2026
- Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaYahoo Finance·Feb 10, 2026
- Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Upstream Bio (UPB): Evaluating Valuation After 10% Share Price SurgeYahoo Finance·Nov 26, 2025
- Upstream Bio to Participate in Upcoming December Investor ConferencesYahoo Finance·Nov 25, 2025
- Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued ProgressYahoo Finance·Nov 5, 2025
- Upstream Bio to Participate in Upcoming November Investor ConferencesYahoo Finance·Oct 31, 2025
All 23 articles loaded
Price Data
Open$9.16
Previous Close$9.12
Day High$9.29
Day Low$8.98
52 Week High$33.68
52 Week Low$7.25
52-Week Range
$7.25$33.68
$9.19
Fundamentals
Market Cap$500M
P/E Ratio—
EPS$-2.66
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume409K
Avg Volume (10D)—
Shares Outstanding54.4M
About Upstream Bio Inc
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—